InVivo gets FDA OK to test bioscaffold in acute SCI patients

04/8/2013 | RTT News

InVivo Therapeutics has received investigational device exemption approval from the FDA to evaluate the use of its biopolymer scaffold in treating patients with acute spinal cord injuries. The study will take place over 15 months, and the company hopes to submit to the FDA the details of the trial by the end of next year.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ